BGI Genomics Co Ltd (300676) - Total Liabilities
Based on the latest financial reports, BGI Genomics Co Ltd (300676) has total liabilities worth CN¥2.81 Billion CNY (≈ $410.62 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 300676 net asset momentum to track the company's year-over-year net asset growth rate.
BGI Genomics Co Ltd - Total Liabilities Trend (2012–2025)
This chart illustrates how BGI Genomics Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See BGI Genomics Co Ltd (300676) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
BGI Genomics Co Ltd Competitors by Total Liabilities
The table below lists competitors of BGI Genomics Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gudang Garam Tbk
JK:GGRM
|
Indonesia | Rp12.80 Trillion |
|
Guangshen Railway Co Ltd
SHG:601333
|
China | CN¥8.07 Billion |
|
BREVILLE GROUP LTD
F:HDE
|
Germany | €507.50 Million |
|
Amot Investments Ltd
TA:AMOT
|
Israel | ILA12.18 Billion |
|
Trump Media & Technology Group Corp.
NASDAQ:DJT
|
USA | $983.45 Million |
|
Santos Brasil Participações S.A
SA:STBP3
|
Brazil | R$4.72 Billion |
|
OneStream, Inc. Class A Common Stock
NASDAQ:OS
|
USA | $386.58 Million |
|
Eternal Materials Co Ltd
TW:1717
|
Taiwan | NT$32.05 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down BGI Genomics Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of BGI Genomics Co Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BGI Genomics Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BGI Genomics Co Ltd (2012–2025)
The table below shows the annual total liabilities of BGI Genomics Co Ltd from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥3.14 Billion ≈ $459.70 Million |
-3.95% |
| 2024-12-31 | CN¥3.27 Billion ≈ $478.60 Million |
-9.37% |
| 2023-12-31 | CN¥3.61 Billion ≈ $528.11 Million |
-13.32% |
| 2022-12-31 | CN¥4.16 Billion ≈ $609.28 Million |
-13.49% |
| 2021-12-31 | CN¥4.81 Billion ≈ $704.26 Million |
-9.60% |
| 2020-12-31 | CN¥5.32 Billion ≈ $779.04 Million |
+251.02% |
| 2019-12-31 | CN¥1.52 Billion ≈ $221.94 Million |
+51.36% |
| 2018-12-31 | CN¥1.00 Billion ≈ $146.62 Million |
+17.35% |
| 2017-12-31 | CN¥853.88 Million ≈ $124.95 Million |
+9.82% |
| 2016-12-31 | CN¥777.52 Million ≈ $113.78 Million |
+4.88% |
| 2015-12-31 | CN¥741.37 Million ≈ $108.49 Million |
+27.08% |
| 2014-12-31 | CN¥583.40 Million ≈ $85.37 Million |
-35.14% |
| 2013-12-31 | CN¥899.46 Million ≈ $131.62 Million |
+5.41% |
| 2012-12-31 | CN¥853.31 Million ≈ $124.87 Million |
-- |
About BGI Genomics Co Ltd
BGI Genomics Co., Ltd. engages in the provision of research services, comprehensive precision medicine testing solutions, and health management services in China and internationally. The company offers DNA sequencing services comprising plant/animal/microbial whole genome re-sequencing and de novo sequencing; human whole genome sequencing, long-read human whole genome resequencing, and whole exom… Read more